📊 Analysis NASDAQ:BPMC :
Financial Performance: 90% YoY growth in net-product revenues from U.S. sales of Ayvakit, a drug for certain cancers.
Market Prospects: Positive market response to Ayvakit's unique clinical profile.
CEO's Confidence: CEO's confidence in the company's future contributes to its momentum.
📈 Bullish Sentiment:
Entry Range: Suggested entry...
This chart seems to love itself. Infatuated with its very own "Head and Shoulders" multiple times looking back on the daily!
Waiting for this one to fill out completely before entering puts. No entry without confirmation. Inside channel, recent bounce off weekly resistance point forming its head. Will wait for pinbar to form on support level right where the...
This indicator may be signaling that BPMC's price has further to drop, since it fell below its price logged 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options. Tickeron's A.I.dvisor backtested 79 similar cases where BPMC's Momentum Indicator fell below the 0 level, and 70 of them led to a successful outcome. Odds of...
Why get subbed to to me on Tradingview?
-TOP author on TradingView
-15+ years experience in markets
-Professional chart break downs
-Supply/Demand Zones
-TD9 counts / combo review
-Key S/R levels
-No junk on my charts
-Frequent updates
-Covering FX/crypto/US stocks
-24/7 uptime so constant updates
BPMC: BUY DIPS 50% gains // SWING trade (STOCKS)
IMPORTANT...
Contextual immersion trading strategy idea.
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in genomically defined cancers, rare diseases, and cancer immunotherapy.
The share prose rose after the company had announced the deal with pharma giant Roche (RHHBY) to sell a cancer treatment,...
Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
THE PRICES ARE ON THE 200 WEEKLY SMA AND I HAVE LOST THE OPPORTUNITY TO ENTER AT THE LEVEL OF THE SMA.
But if I count the wave seams starting a 3 wave of amajor III. In this case we will see the prices over the top.
Stop loss on 57.
BMPQ Short Spread,
Cost $1.93
75/70 Exp October 18
Max loss is $125 max gain is $200
Spread is moderate cost reward ratio is decent.
Trending lower however it may hold sideways here and rise we'll see how it pans out. It may fall under its own weight a little bit more into a support zone.
ALTHOUGH THE STOCK HAS JUMPED THIS WEEK, IT IS NOT TO LATE TO GET IN, BUYING PRESSURE IS IMMENSE AND THE STOCK HAS A EASY 50% UPSIDE POTENTIAL LEFT IN THE TANK, ON THE BACK OF GROWING EXPECTATION THE COMPANY WILL HAVE ITS FIRST APPROVED DRUG FOR SALE AND AT LAST GENERATE PROFITS .
AVERAGE ANALYSTS PRICE TARGET $118
AVERAGE ANALYSTS RECOMMENDATION ...
